Spotlight On... FDA approves the first extended-release orally disintegrating tablet for ADHD; Matinas gets clearance to go to PhI; Israeli VC fund looking to finance drug delivery players; and more...

Neos Therapeutics hopes novel drug delivery will help newly approved Adzenys XR-ODT outcompete generic rivals in the ADHD drug market. The tablet disintegrates in the mouth and does not need to be swallowed. "This first ever FDA approval of a product using our proprietary extended-release, orally disintegrating tablet technology is an important milestone for Neos," CEO Vipin Garg said in a statement. "We believe that Adzenys XR-ODT will provide an important innovation for treatment in the ADHD market, and we intend to begin educating healthcare providers about our exciting new product immediately." The amphetamine-based tablet is similar to Shire's ($SHPG) Adderall, but boasts enhanced drug delivery. More from FierceBiotech

> Matinas BioPharma announced FDA clearance to Initiate Phase 1 Clinical Study of its candidate for the treatment of non-Tuberculous mycobacterium infections. More

> Israeli VC fund Sanara Ventures counts drug delivery devices as one of its main areas of interest. Backed by Philips ($PHG) and Teva ($TEVA), the fund is ramping up its support of innovative startups. One of its first portfolio companies makes a specialized inhaler for delivery of drugs deep into the lungs. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.